AstraZeneca resumes clinical trials for its Covid-19 vaccine candidate

AstraZeneca resumes clinical trials for its Covid-19 vaccine candidate

PanARMENIAN.Net - AstraZeneca on Monday, September 14 resumed clinical trials for its Covid-19 vaccine candidate, Reuters reports.

The resumption of the trials for AstraZeneca’s vaccine, one of the most advanced in development and regarded by governments and financial markets as one of the best bets to tackle the health crisis in the months ahead, buoyed stock markets around the world.

Late-stage trials of the vaccine were suspended last week after an illness in a study participant, casting doubts on an early rollout and sending the London-listed company’s shares lower.

Global trials of the vaccine had also been paused following the UK suspension. Brazil has approved restarting the trials and the Serum Institute of India is awaiting permission from the Drugs Controller General of India.

Cambridge-based AstraZeneca’s shares had risen about 11% this year up to their Friday close of 8,429 pence, giving the pharmaceutical giant a market capitalisation of 111 billion pounds ($142 billion).

 Top stories
The Prosecutor’s Office has released surveillance footage and said that one of the detainees in the case, Iveri Melashvili.
Destinations welcomed 900m fewer international tourists in January–October when compared with the same period of 2019.
Austrian authorities said at least one gunman remained on the run at 1am Vienna time on November 3.
Moderna’s proposed price would apply to the United States and other high-income countries.
Partner news